SQZ Biotech, a Boston, MA-based developer of a new generation of cell therapies that harness the body’s natural immune system to combat disease, closed a $16m Series B financing.
The round was led by NanoDimension and Polaris Partners, with participation from other existing and new investors. In conjunction with the funding, Eric Moessinger of NanoDimension joined SQZ’s Board of Directors.
The company intends to use the funds to advance its preclinical immunotherapy programs in oncology and other serious diseases.
Led by Dr. Armon Sharei, CEO, and Kris Elverum, Chief Business Officer, SQZ Biotech has developed proprietary membrane technology (CellSqueeze) that harnesses a patient’s own cells to develop innovative therapies to combat diseases across a broad range of indications. The platform has been developed at the Massachusetts Institute of Technology (MIT) by Drs. Klavs Jensen, Robert Langer, and Armon Sharei.
The company, which entered a $500M partnership with Roche, has also received grants of more than $2m in the last year.